Compare CGEM & CRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGEM | CRCT |
|---|---|---|
| Founded | 2016 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Wholesale Distributors |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 904.7M | 904.7M |
| IPO Year | 2020 | 2021 |
| Metric | CGEM | CRCT |
|---|---|---|
| Price | $13.77 | $3.99 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 8 | 1 |
| Target Price | ★ $30.13 | $3.00 |
| AVG Volume (30 Days) | ★ 881.8K | 464.0K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 22.20% |
| EPS Growth | N/A | ★ 20.69 |
| EPS | N/A | ★ 0.10 |
| Revenue | N/A | ★ $708,780,000.00 |
| Revenue This Year | N/A | $0.08 |
| Revenue Next Year | $5.20 | $0.98 |
| P/E Ratio | ★ N/A | $39.85 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.68 | $3.74 |
| 52 Week High | $16.74 | $7.33 |
| Indicator | CGEM | CRCT |
|---|---|---|
| Relative Strength Index (RSI) | 42.75 | 41.10 |
| Support Level | $12.41 | $3.82 |
| Resistance Level | $16.21 | $4.68 |
| Average True Range (ATR) | 0.94 | 0.20 |
| MACD | -0.16 | -0.03 |
| Stochastic Oscillator | 11.57 | 16.05 |
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Cricut Inc designs and builds a creativity platform that enables users to turn ideas into professional-looking handmade goods. With its connected machines, design apps and accessories, and materials, the users create everything from personalized birthday cards, mugs and T-shirts to large-scale interior decorations. It has two segments including the Platform segment which derives revenue from monthly and annual subscription fees, purchases of digital content, and a minimal amount of the revenue allocated to unspecified future upgrades and enhancements related to the essential software and access to the Company's cloud-based services and Products segment which derives revenue from the sale of its connected machine hardware, and sale of craft, DIY, home decor products and extensions.